community download

Presentation: Influenza Virus Production in an Amniocyte-Derived Human Cell Line

Dr Hartmut Tintrup, Director Marketing & Business Development from CEVEC joined us at the World Vaccine Cell Culture Congress 2012 in Washington to discuss the development of CAP Cells: a human suspension cell line derived from primary amniocytes. The CAP cell line offers significant advantages: stables and high expression of human proteins, human-like post-translational modifications, growth in suspension, high cell density, non-tumour origin, easy accessibility, fast cell line development, stable growth parameters, all of which means that this technology is well suited for vaccine production. Dr Tintrup further details the capabilities of this technology through the discussion of the case study: Influenza virus production in CAP cells.

Why not download the full presentation and discover more about Influenza virus production in an amniocyte-derived human cell line

  • Advantages of serum-free suspension cells versus egg-based production technologies
  • Exploring the potential of CEVEC’s amniocyte production (CAP) cells for high-titer influenza virus production
  • Strategies for process optimization in order to further simplify manufacturing and increase titers


Some quick details

Email Address:*
First name:*
Last name:*
Job Title:*

Remember my details Information

Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Privacy statement »
Manage your email preferences »

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.